Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common supplement slow Parkinson's? new trial aims to find out

NCT ID NCT07312110

Disease control Sponsor: Haukeland University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether D-serine, a dietary supplement, can slow the progression of Parkinson's disease. One hundred people with early-stage Parkinson's will receive either D-serine or a placebo for 58 weeks. Researchers will measure changes in symptoms and brain scans to see if D-serine protects nerve cells and improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
D-serine (a dietary supplement)
What this could lead to
If it works, this could point toward a treatment that slows Parkinson's progression and reduces symptoms, helping people live better longer.
What could go wrong
This is an early Phase 2 trial with only 100 people. It may fail to show benefit, and D-serine might not work for everyone. Side effects are possible, though previous studies suggest it is safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * A clinical diagnosis of PD\* according to the clinically established MDS clinical diagnostic criteria for Parkinson's disease within 5 years. * \[¹²³I\]FP-CIT single photon emission CT (DaTscan) confirming dopaminergic nigrostriatal denervation. * Hoehn and Yahr score \< 3 at enrollment. * Optimal symptomatic PD treatment, not requiring adjustments, for at least 2 weeks. * Age ≥40 and ≤ 80 years at time of enrollment. Exclusion Criteria: * Dementia or neurodegenerative disorder other than PD at baseline visit. * Atypical parkinsonism (PSP, MSA, CBD vascular parkinsonism, or drug induced parkinsonism). * Any known monogenic cause of PD (GBA1 variation is accepted). * Any psychiatric disorder that would interfere with compliance in the study. * Any severe somatic illness that would make the individual unable to comply and participate in the study. * Use of D-serine supplementation within 90 days of enrolment. * Metabolic, neoplastic, or other physically or mentally debilitating disorder at baseline visit. * Active of planned pregnancy during trial period. * Cognitive impairment as measured by the Mini Mental Status Exam MMSE) \< 20. * Weight \< 45 kg. * Urinary albumin/creatinine ratio ≥ 20 mg/mmol at time of enrollment. * Participants will be excluded if they have CKD stage 3 or higher, defined as: * Estimated golumerular filtration rate (eGFR) \< 60 mL/min/1.73min\^2 at screening, calculated using the CKD-EPI 2021 creatinine equation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease (PD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease (PD) Parkinson's disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Akershus University Hospital

    NOT_YET_RECRUITING

    Lørenskog, Akershus, 1478, Norway

  • Bodø Hospital (Nordland Hospital)

    NOT_YET_RECRUITING

    Bodø, Nordland, 8006, Norway

  • Førde Hospital

    NOT_YET_RECRUITING

    Førde, Vestland, 6812, Norway

  • Haugesund Hospital

    NOT_YET_RECRUITING

    Haugesund, Rogaland, 5528, Norway

  • Haukeland University Hospital

    RECRUITING

    Bergen, Vestland, 5021, Norway

  • Molde Hospital

    NOT_YET_RECRUITING

    Molde, Møre og Romsdal, 6412, Norway

  • Nevro Arendal Soerlandsklinikken

    RECRUITING

    Arendal, Agder, 4838, Norway

  • Oslo University Hospital

    RECRUITING

    Oslo, Oslo, 0450, Norway

  • University Hospital of North Norway

    NOT_YET_RECRUITING

    Tromsø, Troms, 9019, Norway

  • Vestre Viken Hospital

    NOT_YET_RECRUITING

    Drammen, Buskerud, 3004, Norway

  • Østfold Hospital

    NOT_YET_RECRUITING

    Sarpsborg, Østfold fylke, 1714, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.